Patents by Inventor Charles Sia
Charles Sia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9095546Abstract: The present invention relates to a vaccine composition against the infection of human respiratory syncytial virus (RSV) comprising a replication-defective recombinant adenovirus carrying a nucleotide sequence encoding the F protein of RSV or fragment thereof. A method of preventing RSV infection-related diseases using the vaccine composition of the present invention is also provided.Type: GrantFiled: July 20, 2009Date of Patent: August 4, 2015Assignee: National Health Research InstitutesInventors: Yen-Hung Chow, Hsiao-Yun Shao, Charles Sia, Pele Chong
-
Publication number: 20110014220Abstract: The present invention relates to a vaccine composition against the infection of human respiratory syncytial virus (RSV) comprising a replication-defective recombinant adenovirus carrying a nucleotide sequence encoding the F protein of RSV or fragment thereof. A method of preventing RSV infection-related diseases using the vaccine composition of the present invention is also provided.Type: ApplicationFiled: July 20, 2009Publication date: January 20, 2011Applicant: National Health Research InstitutesInventors: Yen-Hung Chow, Hsiao-Yun Shao, Charles Sia, Pele Chong
-
Publication number: 20050214748Abstract: The present invention is directed to antigenic peptides and peptide compositions selected from the Membrane glycoprotein (M), the Spike glycoprotein (S), and the Nucleocapsid (N) protein antigens of the SARS coronavirus (SCoV). The present invention is also directed to methods of use of the peptides of the invention, e.g., for the detection of SARS-associated antibodies. Detection methods include enzyme-linked immunosorbent assay (ELISA) or other immunoassay procedures.Type: ApplicationFiled: November 8, 2004Publication date: September 29, 2005Inventors: Chang Wang, Xinde Fang, Tseng Chang, Scott Liu, Shugene Lynn, Charles Sia
-
Publication number: 20050100883Abstract: The present invention is directed to antigenic peptides and peptide compositions selected from the Membrane glycoprotein (M), the Spike glycoprotein (S), and the Nucleocapsid (N) protein antigens of the SARS coronavirus (SCoV). The present invention is also directed to methods of use of the peptides of the invention, e.g., for the detection of SARS-associated antibodies. Detection methods include enzyme-linked immunosorbent assay (ELISA) or other immunoassay procedures.Type: ApplicationFiled: November 12, 2003Publication date: May 12, 2005Inventors: Chang Wang, Xinde Fang, Tseng Chang, Scott Liu, Shugene Lynn, Charles Sia
-
Patent number: 6264954Abstract: Purified and isolated nucleic acid from specific strains of Haemophilus influenzae is provided which encodes at least a portion of the D15 outer membrane protein of Haemophilus. The nucleic acid is used to produce peptides, polypeptides and proteins free of contaminant associated with Haemophilus for purposes of diagnosis and medical treatment. Furthermore, the nucleic acid may be used in the diagnosis of Haemophilus infection. Antisera obtained following immunization with the nucleic acid D15 outer membrane protein or peptides also may be used for the purpose of diagnosis and medical treatment.Type: GrantFiled: October 1, 1997Date of Patent: July 24, 2001Assignee: Aventis Pasteur LimitedInventors: Pele Chong, Wayne Thomas, Yan Ping Yang, Sheena Loosmore, Dwø Yuan Charles Sia, Michel Klein
-
Patent number: 6083743Abstract: Purified and isolated nucleic acid from specific strains of Haemophilus influenzae is provided which encodes at least a portion of the D15 outer membrane protein of Haemophilus. The nucleic acid is used to produce peptides, polypeptides and proteins free of contaminant associated with Haemophilus for purposes of diagnosis and medical treatment. Furthermore, the nucleic acid may be used in the diagnosis of Haemophilus infection. Antisera obtained following immunization with the nucleic acid D15 outer membrane protein or peptides also may be used for the purpose of diagnosis and medical treatment.Type: GrantFiled: August 18, 1998Date of Patent: July 4, 2000Assignee: Connaught Laboratories LimitedInventors: Pele Chong, Wayne Thomas, Yan Ping Yang, Sheena Loosmore, Dwe Yuan Charles Sia, Michel Klein
-
Patent number: 6018019Abstract: The present invention provides immunogenic synthetic peptides which are useful alone or in PRP-conjugates in vaccines against Hemophilus influenza infection. Modifications are possible within the scope of the invention.Type: GrantFiled: October 3, 1994Date of Patent: January 25, 2000Assignee: Connaught Laboratories LimitedInventors: Pele Chong, Ali Kandil, Charles Sia, Michel Klein
-
Patent number: 6013514Abstract: Purified and isolated nucleic acid from specific strains of Haemophilus influenzae is provided which encodes at least a portion of the D15 outer membrane protein of Haemophilus. The nucleic acid is used to produce peptides, polypeptides and proteins free of contaminant associated with Haemophilus for purposes of diagnosis and medical treatment. Furthermore, the nucleic acid may be used in the diagnosis of Haemophilus infection. Antisera obtained following immunization with the nucleic acid D15 outer membrane protein or peptides also may be used for the purpose of diagnosis and medical treatment.Type: GrantFiled: September 12, 1995Date of Patent: January 11, 2000Assignee: Connaught Laboratories LimitedInventors: Pele Chong, Wayne Thomas, Yan Ping Yang, Sheena Loosmore, Dwo Yuan Charles Sia, Michel Klein
-
Patent number: 5985288Abstract: The gene for outer membrane protein P1 of Haemophilus influenzae b is expressed in E. coli. Methods for expression and demonstration of the immunogenicity of recombinant P1 and portions thereof are disclosed, along with an improved method for the purification of P1. The nucleotide sequence of the P1 gene and the derived amino acid sequence of the P1 protein of Haemophilus influenzae type b are disclosed and the methods used to determine the same. Also disclosed are the methods used to clone and express the P1 gene as well as the purification protocol for the P1 gene products (recombinant P1 and P1 fusion proteins). Fourteen peptides are synthesized corresponding to specific sequences of the mature P1 protein. The use of the P1 protein as n immunogens for immunization against the disease caused by Haemophilus influenzae type b and the use of the protein as a carrier for conjugation with an oligosaccharide derived from Haemophilus to generate a potentially efficacious vaccine against the disease, are described.Type: GrantFiled: June 7, 1995Date of Patent: November 16, 1999Assignee: Connaught Laboratories LimitedInventors: Robert S. Munson, Jr., Susan Grass, Pele Chong, Yan-Ping Yang, Raafat Fahim, Dwo Yan Charles Sia, Patrick McVerry, Michel Klein
-
Patent number: 5972349Abstract: Polyribosylribitol phosphate oligosaccharides are produced in a multistep process. The compound of the formula: ##STR1## wherein R.sub.1 is a first protecting group and R.sub.2 is a second protecting group, is coupled to a solid polyethylene glycol monomethyl ether (PEG) support. Following removal of the first protecting group, the resulting compound is coupled with a repeating unit for chain elongation of the formula: ##STR2## The protecting group is removed from the phosphorus atom and the steps of removing the first protecting group, coupling with the repeating unit is repeated until the desired number of repeating units in the oligomer has been terminated. The oligomer then is terminated with a chain terminating molecule of the formula: ##STR3## wherein m is an integer and R.sub.3 is a third protecting group.Type: GrantFiled: June 7, 1995Date of Patent: October 26, 1999Assignee: Connaught Laboratories LimitedInventors: Pele Chong, Ali Kandil, Charles Sia, Michel Klein
-
Patent number: 5817318Abstract: The invention discloses the identification, characterization and use of a synthetic peptide, GPKEPFRDYVDRFYK (p24E), as a T-cell carrier for the appropriate assembly, with defined B-cell epitopes of the HIV-1 envelope protein, for the construction of potential synthetic vaccine candidates against HIV.Type: GrantFiled: June 6, 1995Date of Patent: October 6, 1998Assignee: Connaught Laboratories LimitedInventors: Dwo Yuan Charles Sia, Pele Chong, Michel Klein
-
Patent number: 5679352Abstract: Synthetic peptides have an amino acid sequence corresponding to at least one antigenic determinant of at least one protein, usually a structural protein, particularly the P1, P2 and P6 protein, of Haemophilus influenzae (Hi), particularly type b, and are used as is, in chimeric T-B form, in lipidated form, linked to a carrier molecule, particularly a synthetic PRP molecule and/or polymerized to form molecular aggregates, in vaccines against Hi.Type: GrantFiled: June 7, 1995Date of Patent: October 21, 1997Assignee: Connaught Laboratories LimitedInventors: Pele Chong, Ali Kandil, Charles Sia, Michel Klein